THE LIBRARY: WEBINAR
Pharmaceutical Development for ADCs: Not as Simple as ABC
Formulation, process, and analytical development for ADCs is complex. Join our experts as we discuss ADC structure and function, the development process (including analytical methods, stability, and lyo cyle optimization) and parenteral product development. Register Today!
Latest Commentary
EVENTS
- Supplying Safe Medicines to Patients June 12 — Exton, PA
- DIA 2013 49th Annual MeetingJune 23-27 — Boston, MA
- BioImmersion Three-Day CourseJuly 10-12 — Chicago, IL
Press Releases
- Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
- Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013
- Statistical Challenges in Medical Device Trail Evaluation
- New drug enhances radiation treatment for brain cancer in preclinical studies
- Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
- More Press Releases
Featured Jobs
-
Director, Global Quality Management Systems Job
Celgene Corporation - Basking Ridge NJ US -
Senior Clinical Data Manager
Infinity Pharmaceuticals - Cambridge MA -
Sr. Manufacturing Process Lead Job
Celgene Corporation - Basking Ridge NJ US -
Import/Export Specialist Job
Celgene Corporation - Basking Ridge NJ US -
Senior Manager, QA Global Training Job
Celgene Corporation - Summit NJ US
New week, new winner in the top pharma settlements contest
Last week, when we unveiled our Top 10 Pharma Settlements report, we promised to update it as new deals hit the news. We didn't realize we'd need to fulfill that promise so quickly. Today, GlaxoSmithKline officially announced its $3 billion settlement, which puts it squarely on top of that list.
Pharma's top 10 marketing settlements top $11B
The Justice Department is growing more and more impatient. For more than a decade, its lawyers and investigators have been slapping drugmakers around for their marketing misdoings. They've insisted on bigger and bigger penalties, especially during the last several years, with payments commonly topping $500 million. And yet the whistleblower lawsuits and off-label settlements keep coming.
Pharma herd faces hurdles with pricey new drugs
With drugmakers flocking to lucrative drug markets for specialty care drugs, the bar has risen to get reimbursement and physician uptake of the expensive products. But there are ways to hedge bets in the specialty care game. We covered several such strategies during a panel I moderated at the 2012 BIO International Convention called "Are Healthcare Reimbursement Policies a Barrier to Specialty Care Treatment?" The easy answer to this question is "yes."
FiercePharma is going to Boston for BIO 2012
The FiercePharma team will be relocating to Boston next week for the BIO 2012 International Convention. We are bringing a team of 15 to the show and we'll have daily coverage of the week's events.
Pharma's Top 5 Golden Handshakes of the Last 5 Years
It's an all-too-familiar frustration for pharma shareholders. On the heels of declining revenues and mismanagement, a CEO departs, and then comes the golden handshake.
Who's the sheriff in lab-diagnostics town?
To know that specialized, targeted drugs are pharma's current rallying cry, you didn't have to follow the news out of this month's big cancer meeting. But it's the latest example of how drugmakers are using knowledge of cancer's genetic drivers to develop new treatments.
While we are off for holiday weekend, cargo thieves are not
Top 10 Best-selling Cancer Drugs in 2011
Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development.
Who's missing from the CEO pay list? Short answer: Europeans
After we assembled this year's ranking of pharma's highest-paid CEOs, we took attendance. And as usual, the absences were telling.
The Future of Biopharma Manufacturing
A Bureau of Labor Statistics study found that pharma manufacturing in the U.S. increased output per hour just 0.7% annually from 1987 to 2008.